Are you a legal professional? Visit our professional site

Stronger Warnings Urged for Tamiflu

Article Placeholder Image
By Admin on November 28, 2007 8:18 AM

Manufacturer Roche Laboratories, Inc. should update Tamiflu labeling to include stronger warnings regarding the risk of psychiatric problems in users of the flu medicine, according to a U.S. Food and Drug Administration (FDA) committee. The FDA Pediatric Advisory Committee made its recommendations after evaluating reports of adverse events associated with use of the prescription influenza medication -- including delusions, confusion, and self-injury -- especially in children. The New York Times reports that "nearly 600 cases of psychiatric problems in Tamiflu patients have been reported, with 75 percent of them from Japan."